Volume 6.36 | Sep 25

Prostate Cell News 6.36 September 25, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Loss of STK11 Expression Is an Early Event in Prostate Carcinogenesis and Predicts Therapeutic Response to Targeted Therapy against MAPK/p38
Researchers report that STK11 expression is significantly decreased in prostate cancer compared to normal tissues. Moreover, STK11 protein levels decreased throughout prostate carcinogenesis. [Autophagy] Abstract
Learn More: Standardized Tools for Cancer Research
PUBLICATIONS (Ranked by impact factor of the journal)

SPOP Mutation Leads to Genomic Instability in Prostate Cancer
Scientists showed that SPOP, the most commonly mutated gene in primary prostate cancer, modulates DNA double strand break repair, and that SPOP mutation is associated with genomic instability. [Elife]
Abstract | Full Article

Microvesicle- and Exosome-Mediated Drug Delivery Enhances the Cytotoxicity of Paclitaxel in Autologous Prostate Cancer Cells
Scientists investigated the effectiveness of two different populations of extracellular vesicles (microvesicle- and exosome-enriched) as carriers of paclitaxel to autologous prostate cancer cells. [J Control Release]
Abstract | Graphical Abstract

Genetic Variants of the Autophagy Pathway as Prognostic Indicators for Prostate Cancer
The authors hypothesized that genetic variants of the autophagy pathway may influence clinical outcomes in prostate cancer patients. They genotyped 40 tagging single-nucleotide polymorphisms from seven core autophagy pathway genes in 458 localized prostate cancer patients. [Sci Rep] Full Article

Overexpression of Enhancer of Zeste Homolog 2 (EZH2) Characterizes an Aggressive Subset of Prostate Cancers and Predicts Patient Prognosis Independently from Pre- and Postoperatively Assessed Clinicopathological Parameters
Investigators analyzed prevalence and prognostic impact of EZH2 in prostate cancer. EZH2 expression was analyzed by immunohistochemistry on a tissue microarray containing more than 12,400 prostate cancer specimens. [Carcinogenesis] Abstract

A Mitochondrial DNA Mutation Influences the Apoptotic Effect of Statins on Prostate Cancer
Scientists aimed to determine if mitochondrial DNA background and hence mitochondrial biochemistry can modulate the efficiency of statin as an anti-prostate cancer agent. [Prostate] Abstract

Human Endogenous Retrovirus HERV-K(HML-2) Activity in Prostate Cancer Is Dominated by a Few Loci
Investigators aimed at delineating the extent and repertoire of HML-2 transcription in prostate cancer tissues and cell lines and to define the transcription pattern and biological effects of chromosome 22q11.23. [Prostate] Abstract

Bruton’s Tyrosine Kinase Is a Potential Therapeutic Target in Prostate Cancer
The authors investigated whether Bruton’s tyrosine kinase (BTK) is a potential therapeutic target in prostate cancer. They found that BTK is expressed in prostate cells, with the alternate BTK-C isoform predominantly expressed in prostate cancer cells and tumors. [Cancer Biol Ther] Abstract


Long-Term Follow-Up of a Randomized Trial of Radiation with or without Androgen Deprivation Therapy for Localized Prostate Cancer
Investigators used long-term follow-up data from a randomized trial comparing radiation therapy with vs without androgen deprivation therapy for unfavorable-risk prostate cancer to compare survival and cause-specific mortality by severity of comorbidity. [JAMA] Abstract | Press Release

HAROW: The First Comprehensive Prospective Observational Study Comparing Treatment Options in Localized Prostate Cancer
The authors aimed to collect data on primary treatment decision and follow-up in patients with diagnosed, histologically confirmed localized prostate cancer for up to five years in a prospective observational non-interventional study. Patients were non-randomly allocated to one of the five treatment strategies: hormone therapy, active surveillance, radiation, operation, or watchful waiting. [World J Urol] Abstract

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis
The authors conducted a systematic review and meta-analysis comparing the efficacy and tolerability of intermittent vs continuous androgen deprivation therapy in patients with prostate cancer. [JAMA Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
ESSA Pharma Inc. Receives FDA Approval to Commence Clinical Development
ESSA Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug application to initiate a Phase I/II clinical study of its novel agent, EPI-506, for the treatment of metastatic castration-resistant prostate cancer in patients who have failed current therapies. [ESSA Pharma Inc.] Press Release

Rosetta Genomics Receives U.S. Patent for Treatment of Prostate Cancer
Rosetta Genomics Ltd. announced receipt of a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 14/446,505, titled “Compositions and Methods for the Prognosis and Treatment of Prostate Cancer.” [Rosetta Genomics Ltd. (Business Wire)] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
Canadian Election Spotlights Scientists’ Frustrations
Canadians will head to the polls on October 19th, in a federal election that many scientists hope will mark a turning point after years of declining research budgets and allegations of government censorship. Although science has not emerged as a top issue during the campaign, researchers are fighting to make their concerns heard. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Global Cancer Summit 2015
November 18-20, 2015
Bangalore, India

NEW Innovation and Biomarkers in Cancer Drug Development (IBCD) 2015
December 3-4, 2015
Brussels, Belgium

Visit our events page to see a complete list of events in the prostate cell community.
NEW Staff Scientist – Prostate Cancer Modeling (Fred Hutchinson Cancer Research Center)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Fellow – Prostate Cancer Research (Rutgers Cancer Institute of New Jersey)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Positions – Stem Cell, Development and Cancer Biology (Columbia University Medical Center)

Staff Scientist – Cancer Modeling (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Drug Discovery and Action (University of Illinois)

Bioinformatician (GenomeDx Biosciences)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us